By Steve Gelsi
First-quarter net income totaled $16 million, after excluding taxes
Cresco Labs Inc.’s stock rose Wednesday after the U.S. cannabis-dispensary operator matched analyst estimates for first-quarter revenue, as its loss narrowed.
Cresco Labs (CRLBF) reported a loss of $2.06 million for the three months that ended March 31, down from $27.8 million in the year-ago quarter.
Excluding taxes, first-quarter net income totaled $16 million, the company said.
Cresco Labs does not provide earnings-per-share figures.
Revenue at the Chicago-based multistate cannabis-dispensary operator fell to $184.3 million from $194.2 million in the year-ago quarter.
Cresco Labs matched the FactSet consensus estimate of $184.3 million for first-quarter revenue. Excluding the impact from strategic divestitures, first-quarter revenue was about flat, the company said.
Cresco Labs’ stock was up by 2.7% on Wednesday.
"The recently announced potential federal rescheduling will fundamentally change the future for cannabis and all of its stakeholders," Chief Executive Charles Bachtell said in a statement.
Cresco Labs has maintained a "very strong performance across our retail and branded product business resulting in a 10x increase in operating cash flow year-over-year," he said.
Looking ahead, Cresco Labs sees potential industry catalysts in the launch of the recreational cannabis market in Ohio as well as the planned November vote in Florida on a statewide adult-use ballot question. Efforts to legalize recreational marijuana in the Pennsylvania legislature are continuing.
Prior to Wednesday’s moves, Cresco Labs’ stock has risen by 49% so far in in 2024, ahead of the Nasdaq’s gain of 10%.
Lowering the classification of cannabis to the less restrictive category of Schedule III from its historical Schedule I listing is expected to remove the costly 280E tax-code provision for legal cannabis operators.
Under 280E, cannabis companies are not allowed to claim standard business deductions, and they must pay millions of dollars more in taxes than other businesses.
Trulieve Cannabis Corp. (TCNNF) has already been challenging its 280E tax payments in a $148 million tax-refund filing based on its view of the situation.
Curaleaf Holdings Inc. (CURLF) has said it would save more than $150 million in 2024 taxes if 280E is eliminated.
Also read: Nasdaq finally ‘warming up’ to Canadian cannabis companies with U.S. exposure. Could American growers be next?
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-15-24 1031ET
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.
© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.